Topics

Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

17:05 EDT 17 Sep 2019 | FinanzNachrichten

Conference call and webcast on Wednesday, September 18at 2:30 pm CET/8:30 am EDT TRYbeCA1, Phase 3 trial for eryaspase in second line pancreatic cancer, progressing on planImmune modulation collabo...

Original Article: Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019

NEXT ARTICLE

More From BioPortfolio on "Erytech Pharma S.A.: ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2019"

Quick Search

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...